Transatlantic Taskforce on Antimicrobial Resistance

TATFAR was created in 2009 to address the urgent threat of antimicrobial resistance (AMR). TATFAR’s technical experts from Canada, the European Union (EU), Norway, and the United States (U.S.) collaborate and share best practices to strengthen domestic and global efforts in the fight against AMR.

**TATFAR’S Leadership**

Working together, members strengthen the drug pipeline through actions like:
- Reviewing and suggesting economic incentives to encourage antibacterial drug discovery and development and publishing documents describing these incentives.
- Creating research opportunities through unique partnerships, such as DRIVE-AB, BARDA, and CARB-X to address challenges in combating antibiotic resistance.
- Collaborating with partners to provide funding mechanisms to advance development of therapeutics, diagnostics, and vaccines.
- Aligning clinical trial networks to evaluate novel antimicrobial products among critically important patient populations.
- Working with regulatory agencies in TATFAR countries to streamline the process of approving newly developed antibiotics and alternatives to antibiotics, like vaccines.

**Key Focus Areas**

- Improve antibiotic use in humans and animals
- Prevent infections and their spread
- Strengthen the drug pipeline

**Strategies for Improving the Pipeline of New Antimicrobial Drugs**

KEY AREA 3
TATFAR Members Take Action

TATFAR members implement local strategies to combat AMR by improving the pipeline of new antimicrobial drugs.

Canada

- Supports the development of, and access to, antimicrobial drugs, technologies, and alternate therapies, through research and/or regulatory initiatives.
- Supporting research initiatives that foster the development of novel alternatives to antibiotics, and point-of-care diagnostics that improve the rational use of antibiotics and the clinical management of disease.
- Developing new tools and policy approaches to facilitate access to therapeutic products that target pathogens important to public health.
- Exploring ways to reduce the reliance on antimicrobials in livestock production by facilitating the availability of innovative products and supporting the use of best animal husbandry practices.

EU

- Aims to boost research development, innovation, and collaboration to provide novel solutions and tools to prevent and treat infectious diseases, improve diagnosis, and control the spread of AMR.
- Established and supports public-public and public-private partnerships to strengthen AMR research (e.g., IMI and JPIAMR).
- Organized transatlantic workshops to boost the development of new diagnostics or to improve the clinical development of new therapeutics.
- Analyzing the use of incentives provided by the EU regulatory system as well as new economic models to stimulate the development of new antimicrobials.

Norway

- Invests both nationally and internationally in the discovery and development of antimicrobial therapeutics, diagnostics, and vaccines.
- Co-led the innovation incentives work package of DRIVE-AB.
- Collaborates with international fora, including the Global AMR R&D Hub, to develop strategies for improving the pipeline.

U.S.

- Offers basic, translational, and clinical R&D funding mechanisms to facilitate the discovery and development of new vaccines, diagnostics and therapeutics.
- The National Institutes of Health (NIH) provides grant and contract funding and offers a suite of preclinical testing and manufacturing services to the global research community to help de-risk the development of new products.
- NIH funds clinical research to study new drugs and optimized regimens/combinations of existing drugs.
- BARDA, NIH, and other global funders support CARB-X, a biopharmaceutical accelerator to fill the pipeline of antibacterial products.
- BARDA forms innovative public-private partnerships with industry to support the clinical development and manufacturing of novel antibacterial products addressing AMR by providing non-dilutive funding and access to core services and product development expertise.